Zobrazeno 1 - 10
of 396
pro vyhledávání: '"Stefan Delorme"'
Autor:
Francisco O. Cortés-Ibáñez, Theron Johnson, Mario Mascalchi, Verena Katzke, Stefan Delorme, Rudolf Kaaks
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-9 (2024)
Abstract Cardiac Troponin I (cTnI) could be used to identify individuals at elevated risk of cardiac death in lung cancer (LC) screening settings. In a population-based, randomized LC screening trial in Germany (“LUSI” study) serum cTnI was measu
Externí odkaz:
https://doaj.org/article/70d594c2941c425f8776076556437bb4
Autor:
Nicolas Hohmann, Martin Ronald Sprick, Moritz Pohl, Azaz Ahmed, Jürgen Burhenne, Marietta Kirchner, Lucian Le Cornet, Markus Kratzmann, Jacek Hajda, Albrecht Stenzinger, Karen Steindorf, Stefan Delorme, Heinz‐Peter Schlemmer, Sabine Riethdorf, Ron vanSchaik, Klaus Pantel, Jens Siveke, Thomas Seufferlein, Dirk Jäger, Walter E. Haefeli, Andreas Trumpp, Christoph Springfeld
Publikováno v:
Clinical and Translational Science, Vol 16, Iss 12, Pp 2483-2493 (2023)
Abstract Expression of CYP3A5 protein is a basal and acquired resistance mechanism of pancreatic ductal adenocarcinoma cells conferring protection against the CYP3A and CYP2C8 substrate paclitaxel through metabolic degradation. Inhibition of CYP3A is
Externí odkaz:
https://doaj.org/article/c68c01273a54478990c71f106d610b42
Autor:
Maria Pouyiourou, Bianca N. Kraft, Timothy Wohlfromm, Michael Stahl, Boris Kubuschok, Harald Löffler, Ulrich T. Hacker, Gerdt Hübner, Lena Weiss, Michael Bitzer, Thomas Ernst, Philipp Schütt, Thomas Hielscher, Stefan Delorme, Martina Kirchner, Daniel Kazdal, Markus Ball, Klaus Kluck, Albrecht Stenzinger, Tilmann Bochtler, Alwin Krämer
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-21 (2023)
Abstract Cancer of unknown primary has a dismal prognosis, especially following failure of platinum-based chemotherapy. 10-20% of patients have a high tumor mutational burden (TMB), which predicts response to immunotherapy in many cancer types. In th
Externí odkaz:
https://doaj.org/article/cf29f4d0ded648268fe0196b4aa79152
Autor:
Tatjana Opacic, Stefanie Dencks, Benjamin Theek, Marion Piepenbrock, Dimitri Ackermann, Anne Rix, Twan Lammers, Elmar Stickeler, Stefan Delorme, Georg Schmitz, Fabian Kiessling
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-13 (2018)
The vascular structure of tumors impacts diagnosis, prognosis and drug response; however, imaging methods to analyse this important feature have been hindered by spatial resolution limitations. Here the authors present a tool called motion model ultr
Externí odkaz:
https://doaj.org/article/747bc0f1af124078babc166c0f25b3bc
Autor:
Markus Wennmann, Thomas Hielscher, Laurent Kintzelé, Bjoern H. Menze, Georg Langs, Maximilian Merz, Sandra Sauer, Hans-Ulrich Kauczor, Heinz-Peter Schlemmer, Stefan Delorme, Hartmut Goldschmidt, Niels Weinhold, Jens Hillengass, Marc-André Weber
Publikováno v:
Cancers, Vol 13, Iss 5, p 961 (2021)
The purpose of this study was to analyze size and growth dynamics of focal lesions (FL) as well as to quantify diffuse infiltration (DI) in untreated smoldering multiple myeloma (SMM) patients and correlate those MRI features with timepoint and cause
Externí odkaz:
https://doaj.org/article/6c34fca32be94bbab06eba18bb8cf588
Autor:
Markus Wennmann, Thomas Hielscher, Laurent Kintzelé, Bjoern H. Menze, Georg Langs, Maximilian Merz, Sandra Sauer, Hans-Ulrich Kauczor, Heinz-Peter Schlemmer, Stefan Delorme, Hartmut Goldschmidt, Niels Weinhold, Jens Hillengass, Marc-André Weber
Publikováno v:
Cancers, Vol 12, Iss 9, p 2537 (2020)
The purpose of this study was to assess how different MRI protocols (spinal vs. spinal plus pelvic vs. whole-body (wb)-MRI) affect staging in patients with smoldering multiple myeloma (SMM), according to the SLiM-CRAB-criterion ‘>1 focal lesion (FL
Externí odkaz:
https://doaj.org/article/37defd29efc44255aeee4dbd459cfea2
Autor:
Jennifer Mosebach, Sofia Shah, Stefan Delorme, Thomas Hielscher, Hartmut Goldschmidt, Heinz-Peter Schlemmer, Stefan Schönland, Ute Hegenbart, Jens Hillengass
Publikováno v:
Haematologica, Vol 103, Iss 2 (2018)
Allogeneic stem cell transplantation is a therapeutic option under dispute but nonetheless chosen with increasing frequency for patients suffering from multiple myeloma in Europe. To study possible predictors of survival, 79 patients were investigate
Externí odkaz:
https://doaj.org/article/67af4bd24dfa4bc58335ec31106421e3
Autor:
Sebastian Bickelhaupt, Franziska Steudle, Daniel Paech, Anna Mlynarska, Tristan Anselm Kuder, Wolfgang Lederer, Heidi Daniel, Martin Freitag, Stefan Delorme, Heinz-Peter Schlemmer, Frederik Bernd Laun
Publikováno v:
PLoS ONE, Vol 12, Iss 4, p e0176077 (2017)
To evaluate a fractional order calculus (FROC) model in diffusion weighted imaging to differentiate between malignant and benign breast lesions in breast cancer screening work-up using recently introduced parameters (βFROC, DFROC and μFROC).This re
Externí odkaz:
https://doaj.org/article/d6a0318232c048b1904974cc424d8063
Publikováno v:
Diagnostics, Vol 7, Iss 4, p 61 (2017)
Elotuzumab is the first monoclonal antibody approved for the treatment of relapsed-refractory multiple myeloma (MM) in combination with lenalidomide, an immunodulatory drug, and dexamethasone. We report on a multiply pre-treated MM patient with disea
Externí odkaz:
https://doaj.org/article/a77dea4bf60a4f68bce7cb5af22cd052
Autor:
Tobias Bäuerle, Heidegard Hilbig, Sönke Bartling, Fabian Kiessling, Astrid Kersten, Annette Schmitt-Gräff, Hans-Ulrich Kauczor, Stefan Delorme, Martin R. Berger
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 10, Iss 5, Pp 511-520 (2008)
The aim of this study was to evaluate the effect of an antiangiogenic treatment with the vascular endothelial growth factor antibody bevacizumab in an experimental model of breast cancer bone metastasis and to monitor osteolysis, soft tissue tumor, a
Externí odkaz:
https://doaj.org/article/01117515467d4096a4dc14a22fbb6f2c